SCTB14 / Sinocelltech - LARVOL DELTA

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. (clinicaltrials.gov) - P3 | N=246 | Recruiting | Sponsor: Sinocelltech Ltd.

IO biomarker • New P3 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. (clinicaltrials.gov) - P1/2 | N=515 | Not yet recruiting | Sponsor: Sinocelltech Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor